The previous pop back to old purple bottoms line predicted here in September fizzled a bit at the top peaking early around $2.55 instead of the expected $2.75-3.00. Now we're filling in leg E of the giant corrective wedge since July 2020 $10 high. While the shareholder vote this morning did not meet its quorum requirement, the good news is this morning's retest...
TEST
CytoDyn, Inc. is a clinical-stage biotechnology company, which engages in the development of innovative treatments for multiple therapeutic indications based on leronlimab. Its product include HIV, Cancer, graft-versus-host disease (GVHD), and COVID-19. The company was founded by Allen D. Allen on May 2, 2002 and is headquartered in Vancouver, WA.
TEST
It's not your textbook hns
CytoDyn, Inc. is a clinical-stage biotechnology company, which engages in the development of innovative treatments for multiple therapeutic indications based on leronlimab. Its product include HIV, Cancer, graft-versus-host disease (GVHD), and COVID-19. The company was founded by Allen D. Allen on May 2, 2002 and is headquartered in...
CYDY performance has been dismal since the out-of-protocol "hold your horses!" FDA letter in late May, continuing down in a withering C wave. A great article posted by our friends KenChowder and ohm on Democrat blog dailykos.com yesterday was angrily removed by complainers conditioned to treat any good news on therapeutics as crazy Trumpist propaganda from the...
The FDA explanatory letter this week dropped Cytodyn to $1.77 Wednesday, lower than March $2 low but higher than November $1.63 low. We have a nice clean 5-wave impulse up off the lows back to $2.19 to end the week. It's tiny so far but at least a sign that Wednesday was washout low. So I'm sticking with the year-long 5-wave triangle correction as main thesis...
CYDY has rallied strongly from the $2 floor the past week, doubling to $4.2 this morning on recent understanding that results of CD12 study were hampered by the FDA's 2-dose limitation. With 4-doses spread over the 4-week patient evaluations, more severe patients would likely have been saved.
If we conservatively stick to the consolidation triangle idea coming...
There was a disappointing drop in price after my first posting. (see link below). Since then there has been very encouraging news on one of its drugs. The good news: Although in small trials, the drug appears to be very helpful in assisting treatment in severe infections with Covid-19. Bad news: multiple law firms are suing CYDY as these opportunistic firms do. ...
Though CYDY managed to rally over the winter from 1.85 to 7.4 on COVID trial results speculation, the 1,2,i,ii,iii nesting sequence we spotted in December never materialized into the expected sequence of higher highs iv,v,4,5 into $8 and $9. The rally stretched and distorted in time ending as a 5-wave B-wave fakeout to $7.4 in February. A sharp C-wave correction...
Cytodyn Inc. (CYDY) is another biotech. It uses viral immunology to develop treatments for HIV, Covid-19 treatment, and NASH (nonalcoholic steatohepatitis). NASH is greatly on the rise.
The Price action from 2006 to 2020 could be seen as an irregular "W" base. Price has gone the major resistance line (1) now twice on a big upswing in volume. There is a...
Bullish Flag
Pros:
Descending volume during formation
Golden cross in blue
PPS above 50MA and 200MA
RS above 0, and ascending
ATR Ascending
R/R ratio above 8
200MA ascending
250RSI below 50
If confirmed:
PT = 10.465$
CYDY is following last week's projection well, spiking parabolically higher to $7 instead of $6 but coming back to $4.5 support area as indicated. Here are my longer-term CYDY wave labels. Interestingly we're once again approaching the original central pitchfork channel started in November 2019 at $.26. That may provide some immediate resistance around $8 but...
Cytodyn appears to be the "last man standing" amongst pharmaceutical treatments intended to stop the Cytokine storm that consumes severe COVID patients. It's Leronlimab trial is still anticipated to significantly reduce mortality and quickly get severe patients off ventilators when all competing drugs have fallen short of proving more than a few days reduced...
So far we haven't seen any indication that FDA or other agencies are in a hurry to approve Cytodyn's Emergency Use Authorization request or otherwise accelerate their trial and manufacturing process, despite Cytodyn's strong Phase II blind trial results and leadership in the race amongst pharmas to convincingly prove out a strongly safe and effective COVID...
